Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges

Theranostics

Volumn 4, Issue 9, 2014, Pages 931-944

  Zhu, Jie ^a   Huang, He ^b   Dong, Shiwu ^b   Ge, Liang ^c   Zhang, Yuan ^b,c  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aptamer; Biomarker; Chemotherapy; Drug delivery; Nanomedicine

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; APTAMER; CURCUMIN; DAUNORUBICIN; DNA; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIRUBICIN; FLUOROURACIL; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; LIPOSOME; MICRORNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OLIGONUCLEOTIDE; PLATINUM DERIVATIVE; RNA; ROTENONE; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; DRUG CARRIER; PROTEIN BINDING; TUMOR MARKER;

APOPTOSIS; CARCINOGENESIS; CELL SURFACE; CONJUGATION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSPORT; GENE SEQUENCE; GENETIC HETEROGENEITY; HUMAN; MULTIDRUG RESISTANCE; NANOMEDICINE; NANOTECHNOLOGY; PUBLIC HEALTH; REVIEW; RNA INTERFERENCE; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; TUMOR XENOGRAFT; UBIQUITINATION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; NEOPLASMS;

AMINO ACID SEQUENCE; ANIMALS; APTAMERS, NUCLEOTIDE; DRUG CARRIERS; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROTEIN BINDING; TUMOR MARKERS, BIOLOGICAL;

EID: 84904556681     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.9663     Document Type: Review

References (114)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
2. Zhang Y, Hong H, Cai W. Tumor-targeted drug delivery with aptamers. Curr Med Chem. 2011; 18: 4185-94.
3. Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014; 26: 48-58.
4. Zheng W, McLerran DF, Rolland BA, et al. Burden of Total and Cause-Specific Mortality Related to Tobacco Smoking among Adults Aged ≥45 Years in Asia: A Pooled Analysis of 21 Cohorts. PLoS Med. 2014; 11: e1001631.
5. Shapira A, Livney YD, Broxterman HJ, et al. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat. 2011; 14: 150-63.
6. Hubbell JA, Langer R. Translating materials design to the clinic. Nat Mater. 2013; 12: 963-6.
7. Zhang XQ, Xu X, Bertrand N, et al. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev. 2012; 64: 1363-84.
8. Kobayashi H, Watanabe R, Choyke PL. Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?. Theranostics. 2014; 4: 81-9.
9. Hughes B. Antibody-drug conjugates for cancer: poised to deliver? Nat Rev Drug Discov. 2010; 9: 665-7.
10. You J, Zhang R, Xiong C, et al. Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res. 2012; 72: 4777-86.
11. D'Huyvetter M, Vincke C, Xavier C, et al. Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody. Theranostics 2014; 4: 708-20.
12. Sundaram P, Kurniawan H, Byrne ME, et al. Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci. 2013; 48: 259-71.
13. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006; 5: 123-32.
14. Bunka DH, Stockley PG. Aptamers come of age - at last. Nat Rev Microbiol. 2006; 4: 588-96.
15. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, et al. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 2008; 26: 442-9.
16. Sefah K, Shangguan D, Xiong X, et al. Development of DNA aptamers using Cell-SELEX. Nat Protoc. 2010; 5: 1169-85.
17. Yang X, Bassett SE, Li X, et al. Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing. Nucleic Acids Res. 2002; 30: e132.
18. Tesmer VM, Lennarz S, Mayer G, et al. Molecular mechanism for inhibition of g protein-coupled receptor kinase 2 by a selective RNA aptamer. Structure. 2012; 20: 1300-9.
19. Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008; 105: 17356-61.
20. Lu W, Arumugam SR, Senapati D, et al. Multifunctional oval-shaped gold-nanoparticle-based selective detection of breast cancer cells using simple colorimetric and highly sensitive two-photon scattering assay. ACS Nano. 2010; 4: 1739-49.
21. Yen SK, Padmanabhan P, Selvan ST. Multifunctional Iron Oxide Nanoparticles for Diagnostics, Therapy and Macromolecule Delivery. Theranostics. 2013; 3: 986-1003.
22. Ding K, Alemdaroglu FE, Börsch M, et al. Engineering the structural properties of DNA block copolymer micelles by molecular recognition. Angew Chem Int Ed Engl. 2007; 46: 1172-5.
23. Bagalkot V, Farokhzad OC, Langer R, et al. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl. 2006; 45: 8149-52.
24. Zhang Z, Ali MM, Eckert MA, et al. A polyvalent aptamer system for targeted drug delivery. Biomaterials. 2013; 34: 9728-35.
25. Huang YF, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem. 2009; 10: 862-8.
26. Zhu G, Zheng J, Song E, et al. Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc Natl Acad Sci U S A. 2013; 110: 7998-8003.
27. Han D, Zhu G, Wu C, et al. Engineering a cell-surface aptamer circuit for targeted and amplified photodynamic cancer therapy. ACS Nano. 2013; 7: 2312-9.
28. Zhu G, Hu R, Zhao Z, et al. Noncanonical self-assembly of multifunctional DNA nanoflowers for biomedical applications. J Am Chem Soc. 2013; 135: 16438-45.
29. Douglas SM, Bachelet I, Church GM. A logic-gated nanorobot for targeted transport of molecular payloads. Science. 2012; 335: 831-4.
30. Jiang Q, Song C, Nangreave J, et al. DNA origami as a carrier for circumvention of drug resistance. J Am Chem Soc. 2012; 134: 13396-403.
31. Wu Y, Sefah K, Liu H, et al. DNA aptamer-micelle as an efficient detection/ delivery vehicle toward cancer cells. Proc Natl Acad Sci U S A. 2010; 107: 5-10.
32. Wu C, Han D, Chen T, et al. Building a multifunctional aptamer-based DNA nanoassembly for targeted cancer therapy. J Am Chem Soc. 2013; 135: 18644-50.
33. Mongelard F, Bouvet P. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr Opin Mol Ther. 2010; 12: 107-14.
34. Hovanessian AG, Soundaramourty C, El Khoury D, et al. Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PLoS One. 2010; 5: e15787.
35. Xing H, Tang L, Yang X, et al. Selective Delivery of an Anticancer Drug with Aptamer-Functionalized Liposomes to Breast Cancer Cells in Vitro and in Vivo. J Mater Chem B Mater Biol Med. 2013; 1: 5288-5297.
36. Soundararajan S, Chen W, Spicer EK, et al. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008; 68: 2358-65.
37. Girvan AC, Teng Y, Casson LK, et al. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol Cancer Ther. 2006; 5: 1790-9.
38. Laber DA, Sharma VR, Bhupalam L, et al. Update on the first phase I study of AGRO100 in advanced cancer. J Clin Oncol 2005; 23: 3064.
39. Chen W, Sridharan V, Soundararajan S et al. Activity and mechanism of action of AS1411 in acute myeloid leukemia cells. Blood. 2007; 110: 479-84.
40. Rosenberg JE, Bambury RM, Van Allen EM, et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs. 2014; 32: 178-87.
41. Ristau BT, O'Keefe DS, Bacich DJ. The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research. Urol Oncol. 2014; 32: 272-79.
42. Kolishetti N, Dhar S, Valencia PM, et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A. 2010; 107: 17939-44.
43. Gu F, Zhang L, Teply BA, Mann N, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A. 2008; 105: 2586-91.
44. Kim D, Jeong YY, Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano. 2010; 4: 3689-96.
45. Jalalian SH, Taghdisi SM, Shahidi Hamedani N, et al. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur J Pharm Sci. 2013; 50: 191-7.
46. Zhao N, You J, Zeng Z et al. An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells. Small. 2013; 9: 3477-84.
47. Li L, Xiang D, Shigdar S, et al. Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells. Int J Nanomedicine. 2014; 9: 1083-96
48. Liu Z, Duan JH, Song YM, et al. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med. 2012; 10: 148.
49. Hu Y, Duan J, Zhan Q, et al. Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS One. 2012; 7: e31970.
50. Bandekar A, Zhu C, Jindal R, et al. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer. J Nucl Med. 2014; 55: 107-14.
51. Farin K, Schokoroy S, Haklai R, et al. Oncogenic synergism between ErbB1, nucleolin, and mutant Ras. Cancer Res. 2011; 71: 2140-51.
52. Sekar TV, Foygel K, Ilovich O, et al. Noninvasive Theranostic Imaging of HSV1-sr39TK-NTR/GCV-CB1954 Dual-Prodrug Therapy in Metastatic Lung Lesions of MDA-MB-231 Triple Negative Breast Cancer in Mice. Theranostics. 2014; 4: 460-74.
53. Bhatia S, Frangioni JV, Hoffman RM et al. The challenges posed by cancer heterogeneity. Nat Biotechnol. 2012; 30: 604-10.
54. Denison TA, Bae YH. Tumor heterogeneity and its implication for drug delivery. J Control Release. 2012; 164: 187-91.
55. Hoey T. Drug resistance, epigenetics, and tumor cell heterogeneity. Sci Transl Med. 2010; 2: 28ps19.
56. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; 501: 346-54.
57. Wilting RH, Dannenberg JH. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat. 2012; 15: 21-38.
58. Burke DH, Willis JH. Recombination, RNA evolution, and bifunctional RNA molecules isolated through chimeric SELEX. RNA. 1998; 4: 1165-75.
59. Zhu G, Meng L, Ye M, et al. Self-assembled aptamer-based drug carriers for bispecific cytotoxicity to cancer cells. Chem Asian J. 2012; 7: 1630-6.
60. Lu W, Arumugam SR, Senapati D, et al. Multifunctional oval-shaped gold-nanoparticle-based selective detection of breast cancer cells using simple colorimetric and highly sensitive two-photon scattering assay. ACS Nano. 2010; 4: 1739-49.
61. Min K, Jo H, Song K, et al. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials. 2011; 32: 2124-32.
62. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012; 21: 283-96.
63. Qu H, Li R, Liu Z, et al. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol. 2013; 6: 2644-50.
64. Wang R, Liu W, Helfer CM, et al. Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma. Cancer Res. 2014; 74: 3332-43.
65. Kwan JJ, Kaya M, Borden MA, et al. Theranostic Oxygen Delivery Using Ultrasound and Microbubbles. Theranostics. 2012; 2: 1174-84.
66. Shapira A, Livney YD, Broxterman HJ, et al. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat. 2011; 14: 150-63.
67. Denison TA, Bae YH. Tumor heterogeneity and its implication for drug delivery. J Control Release. 2012; 164: 187-91.
68. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer. 2010; 10: 505-14.
69. Wu W, Chen H, Shan F et al. A Novel Doxorubicin-Loaded in Situ Forming Gel Based High Concentration of Phospholipid for Intratumoral Drug Delivery. Mol Pharm 2014; [Epub ahead of print].
70. Kaelin WG Jr. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol. 2011; 76: 335-45.
71. Guarente L. The many faces of sirtuins: Sirtuins and the Warburg effect. Nat Med. 2014; 20: 24-5.
72. Lum JJ, Bui T, Gruber M, et al. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 2007; 21: 1037-49.
73. Rankin EB, Rha J, Selak MA, et al. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol Cell Biol. 2009; 29: 4527-38
74. Greco O, Marples B, Joiner MC, et al. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol. 2003; 197: 312-25.
75. Baker LC, Boult JK, Walker-Samuel S, et al. The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function. Br J Cancer. 2012; 106: 1638-47.
76. Lu H, Li X, Luo Z, et al. Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A. Mol Cancer Ther. 2013; 12:2187-99.
77. Zhang J, Cao J, Weng Q, et al. Suppression of hypoxia-inducible factor 1α (HIF-1α) by tirapazamine is dependent on eIF2α phosphorylation rather than the mTORC1/4E-BP1 pathway. PLoS One. 2010; 5: e13910.
78. Chen ZS, Tiwari AK. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J. 2011; 278: 3226-45.
79. Chen Y, Bathula SR, Li J, et al. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem. 2010; 285: 22639-50.
80. Patil YB, Swaminathan SK, Sadhukha T, et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 2010; 31: 358-65.
81. Wu J, Lu Y, Lee A, et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci. 2007; 10: 350-7.
82. Chen Y, Zhang L, Lu X, et al. Sinomenine reverses multidrug resistance in bladder cancer cells via P-glycoprotein-dependent and independent manners. Pharmazie. 2014; 69: 48-54.
83. Liu Y, Li LL, Qi GB, et al. Dynamic disordering of liposomal cocktails and the spatio-temporal favorable release of cargoes to circumvent drug resistance. Biomaterials. 2014; 35: 3406-15.
84. Zhang H, Wang J, Cai K, et al. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells. J Cancer Res Ther. 2012; 8: 226-31.
85. Perche F, Biswas S, Wang T, et al. Hypoxia-Targeted siRNA Delivery. Angew Chem Int Ed Engl. 2014; 53: 3362-6.
86. Chung LW, Baseman A, Assikis V, et al. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol. 2005; 173: 10-20.
87. Sanità P, Capulli M, Teti A, et al. Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer. 2014; 14: 154.
88. Yu Y, Xiao CH, Tan LD, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br J Cancer. 2014; 110: 724-32.
89. Hale MD, Hayden JD, Grabsch HI. Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response. Cell Oncol (Dordr). 2013; 36: 95-112.
90. Choi YP, Lee JH, Gao MQ, et al. Cancer-associated fibroblast promote transmigration through endothelial brain cells in three-dimensional in vitro models. Int J Cancer 2014; [Epub ahead of print].
91. Obeid E, Nanda R, Fu YX, et al. The role of tumor-associated macrophages in breast cancer progression. Int J Oncol. 2013; 43: 5-12.
92. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4: 71-8.
93. Rupp C, Scherzer M, Rudisch A, et al. IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction. Oncogene 2014; [Epub ahead of print].
94. Andersen MN, Abildgaard N, Maniecki MB, et al. Monocyte/ macrophage-derived soluble CD163: a novel biomarker in multiple myeloma. Eur J Haematol 2014; [Epub ahead of print].
95. Hall CL, Dai J, van Golen KL, et al. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res. 2006; 66: 8648-54.
96. Moro L, Arbini AA, Marra E, et al. Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation. J Biol Chem. 2005; 280: 22482-91
97. Kiefer JA, Farach-Carson MC. Type I collagen-mediated proliferation of PC3 prostate carcinoma cell line: implications for enhanced growth in the bone microenvironment. Matrix Biol. 2001; 20: 429-37.
98. Yang H, Liu H, Kang H, et al. Engineering target-responsive hydrogels based on aptamer-target interactions. J Am Chem Soc. 2008; 130: 6320-1.
99. Yang L, Zhang X, Ye M, et al. Aptamer-conjugated nanomaterials and their applications. Adv Drug Deliv Rev. 2011; 63: 1361-70.
100. Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 2009; 8: 543-57.
101. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009; 8: 129-38.
102. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 2007; 59: 748-58.
103. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2012; 64: 353-65.
104. Guo J, Gao X, Su L, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011; 32: 8010-20.
105. Buggins AG, Pepper C, Patten PE, et al. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res. 2010; 70: 7523-33.
106. Kim HJ, Yim GW, Nam EJ, et al. Synergistic Effect of COX-2 Inhibitor on Paclitaxel-Induced Apoptosis in the Human Ovarian Cancer Cell Line OVCAR-3. Cancer Res Treat. 2014; 46: 81-92.
107. Li Z, Guo Y, Jiang H, et al. Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype. BMC Cancer. 2014; 14: 276.
108. Mi J, Zhang X, Rabbani ZN, et al. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther. 2008; 16: 66-73.
109. Srinivasan S, Selvan ST, Archunan G, et al. MicroRNAs -the Next Generation Therapeutic Targets in Human Diseases. Theranostics. 2013; 3: 930-42.
110. Xu X, Xie K, Zhang XQ, et al. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci U S A. 2013; 110: 18638-43.
111. Draz MS, Fang BA, Zhang P, et al. Nanoparticle-Mediated Systemic Delivery of siRNA for Treatment of Cancers and Viral Infections. Theranostics. 2014; 4: 872-92.
112. Rosenblum D, Peer D. Omics-based nanomedicine: The future of personalized oncology. Cancer Lett. 2013; doi: 10.1016/j.canlet.2013.07.029.
113. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013; 339: 1546-58.
114. Zhang Y, Hong H, Cai W. Tumor-targeted drug delivery with aptamers. Curr Med Chem. 2011; 18: 4185-94.